2 Immune related adverse events in endometrial cancer: a biomarker for treatment efficacy?
Objectives: Immunotherapy (IO), either as single agent or in combination (ex: pembrolizumab +/- lenvatinib), is a critical tool in the treatment of advanced/metastatic endometrial cancer (EC). In other tumor types, the incidence of immune related adverse events (irAEs) correlates with improved outco...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2023-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |